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A bs tr ac t
Background
Thrombin potently activates platelets through the protease-activated receptor PAR-1. 
Vorapaxar is a novel antiplatelet agent that selectively inhibits the cellular actions of 
thrombin through antagonism of PAR-1.
Methods
We randomly assigned 26,449 patients who had a history of myocardial infarction, 
ischemic stroke, or peripheral arterial disease to receive vorapaxar (2.5 mg daily) or 
matching placebo and followed them for a median of 30 months. The primary effi-
cacy end point was the composite of death from cardiovascular causes, myocardial 
infarction, or stroke. After 2 years, the data and safety monitoring board recom-
mended discontinuation of the study treatment in patients with a history of stroke 
owing to the risk of intracranial hemorrhage.
Results
At 3 years, the primary end point had occurred in 1028 patients (9.3%) in the vora-
paxar group and in 1176 patients (10.5%) in the placebo group (hazard ratio for the 
vorapaxar group, 0.87; 95% confidence interval [CI], 0.80 to 0.94; P<0.001). Cardio-
vascular death, myocardial infarction, stroke, or recurrent ischemia leading to revascu-
larization occurred in 1259 patients (11.2%) in the vorapaxar group and 1417 patients 
(12.4%) in the placebo group (hazard ratio, 0.88; 95% CI, 0.82 to 0.95; P = 0.001). 
Moderate or severe bleeding occurred in 4.2% of patients who received vorapaxar 
and 2.5% of those who received placebo (hazard ratio, 1.66; 95% CI, 1.43 to 1.93; 
P<0.001). There was an increase in the rate of intracranial hemorrhage in the vora-
paxar group (1.0%, vs. 0.5% in the placebo group; P<0.001).
Conclusions
Inhibition of PAR-1 with vorapaxar reduced the risk of cardiovascular death or isch-
emic events in patients with stable atherosclerosis who were receiving standard ther-
apy. However, it increased the risk of moderate or severe bleeding, including intra-
cranial hemorrhage. (Funded by Merck; TRA 2P–TIMI 50 ClinicalTrials.gov number, 
NCT00526474.)
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Platelets play a central role in ath-erothrombosis and are an important target for pharmacotherapy. In patients with acute 
coronary syndromes, the use of potent platelet 
inhibitors has been shown to reduce the rate of 
thrombotic events at the cost of increased bleed-
ing.1-3 In contrast, among patients with stable 
atherosclerosis, a reduced rate of thrombotic events 
with antiplatelet therapy in addition to aspirin ther-
apy has not been established.4
Thrombin is a serine protease that is critical 
in thrombosis. In addition to generating fibrin, 
thrombin is a potent agonist of platelets through 
interaction with protease-activated receptors 
(PARs).5 Vorapaxar (SCH 530348, Merck) is a com-
petitive and selective antagonist of PAR-1, the ma-
jor thrombin receptor on human platelets. Vora-
paxar potently inhibits thrombin-induced platelet 
aggregation.6,7 This study, called the Thrombin 
Receptor Antagonist in Secondary Prevention of 
Atherothrombotic Ischemic Events (TRA 2P)–
Thrombolysis in Myocardial Infarction (TIMI) 50 
trial, was designed to evaluate the efficacy and 
safety of vorapaxar in reducing atherothrombotic 
events in patients with established atherosclerosis 
who were receiving standard therapy. In addition 
to investigating vorapaxar specifically, the trial 
more broadly tested the hypothesis that the in-
tensification of antiplatelet therapy by adding an 
agent with a different pharmacologic target is ben-
eficial for secondary prevention in patients with 
stable disease and a history of myocardial infarc-
tion, ischemic stroke, or peripheral arterial disease.
Me thods
Study Design and Oversight
The TRA 2P–TIMI 50 trial was a multinational, 
double-blind, placebo-controlled trial8 that was 
conducted at 1032 sites in 32 countries (see the 
Supplementary Appendix, available with the full 
text of this article at NEJM.org). The trial was spon-
sored by Merck and was designed by the TIMI Study 
Group in conjunction with the steering commit-
tee and trial sponsor. The protocol was approved by 
the relevant ethics committees at all participating 
centers. The raw database was provided to the TIMI 
Study Group, which carried out the data analyses 
independently of the sponsor, prepared this report, 
and made the decision to submit the manuscript 
for publication. The members of the TIMI Study 
Group assume responsibility for the accuracy and 
completeness of the data and all analyses and for 
the fidelity of this report to the study protocol, 
which is available at NEJM.org.
Study Population
Eligible patients had a history of atherosclerosis, 
which was defined as a spontaneous myocardial 
infarction or ischemic stroke within the previous 
2 weeks to 12 months or peripheral arterial dis-
ease associated with a history of intermittent 
claudication in conjunction with either an ankle–
brachial index of less than 0.85 or previous revas-
cularization for limb ischemia. By design, enroll-
ment of patients with a qualifying diagnosis of 
either stroke or peripheral arterial disease was to 
end when the number enrolled reached approxi-
mately 15% of the total anticipated sample size.
Patients were ineligible if they were planning 
to undergo a revascularization procedure, had a 
history of bleeding diathesis, had recent active ab-
normal bleeding, were receiving ongoing treatment 
with warfarin, or had active hepatobiliary disease. 
The full eligibility criteria have been reported previ-
ously.8 Written informed consent was obtained 
from all patients.
Randomization and Study Treatment
Eligible patients were randomly assigned in a 1:1 
ratio to receive either vorapaxar (2.5 mg daily) or 
matched placebo by a central computerized system 
with hierarchical stratification according to the 
qualifying diagnosis (myocardial infarction, stroke, 
or peripheral arterial disease) and the responsible 
physician’s intent to administer a thienopyridine 
(see the Methods section in the Supplementary Ap-
pendix). Vorapaxar and placebo were administered 
orally in a blinded fashion once daily until the end 
of follow-up. Study therapy was to be interrupted 
if the patient required treatment with either a 
potent inhibitor of the cytochrome P-450 3A4 
(CYP3A4) enzyme system or warfarin in conjunc-
tion with a thienopyridine. All concomitant medi-
cal therapy, including the use of other antiplate-
let agents, was managed by the clinicians at the 
study sites who were responsible for the care of 
the patients, according to local standards of care.
In January 2011, after completion of enrollment 
and a median of 24 months of follow-up, the data 
and safety monitoring board reported an excess of 
intracranial hemorrhage in patients with a history 
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of stroke in the vorapaxar group and recommend-
ed discontinuation of the drug in all patients with 
previous stroke, including those with a new stroke 
during the trial. The board also recommended 
continuation of the trial in patients without a 
history of stroke. The protocol was amended ac-
cordingly (see the Methods section in the Supple-
mentary Appendix).
End Points
The protocol-defined primary efficacy end point 
was a composite of cardiovascular death, myocar-
dial infarction, stroke, or recurrent ischemia lead-
ing to urgent coronary revascularization. The major 
secondary end point was a composite of cardio-
vascular death, myocardial infarction, or stroke. 
Before the database was locked and during blind-
ed treatment, the investigators reviewed data from 
the newly completed Thrombin Receptor Antag-
onist for Clinical Event Reduction in Acute Coro-
nary Syndrome (TRACER) trial (ClinicalTrials.gov 
number, NCT00527943).9 On the basis of data from 
that trial, the steering committee amended the 
main data-analysis plan to reorder the hierarchy 
of efficacy analyses, defining as the primary end 
point the composite of cardiovascular death, myo-
cardial infarction, or stroke. The composite of car-
diovascular death, myocardial infarction, stroke, 
or urgent coronary revascularization became the 
major secondary end point. Definitions of the com-
ponents of these composite end points are provided 
in the Supplementary Appendix.
We assessed bleeding using the Global Use of 
Strategies to Open Occluded Coronary Arteries 
(GUSTO) classification system and the TIMI clas-
sification system, with GUSTO moderate or severe 
bleeding defined as the safety end point of pri-
mary interest. A clinical-events committee whose 
members were unaware of the study-group as-
signments adjudicated all components of the pri-
mary and major secondary efficacy end points and 
bleeding episodes.
Statistical Analysis
We calculated that 2279 events would be required 
to provide a power of at least 90% to detect a 15% 
relative risk reduction in the composite end point of 
cardiovascular death, myocardial infarction, stroke, 
or urgent coronary revascularization in the vora-
paxar group, as compared with the placebo group. 
We estimated that 1400 events would be required 
to provide a power of at least 85% to detect the 
same relative treatment effect with respect to the 
composite end point of cardiovascular death, myo-
cardial infarction, or stroke.
The primary efficacy analysis was conducted on 
an intention-to-treat basis among all patients who 
underwent randomization. After the data and 
safety monitoring board recommended discon-
tinuation of vorapaxar in all patients with previ-
ous stroke, the protocol was amended to include 
supplementary evaluation of efficacy in patients 
who qualified for the trial with a diagnosis of 
myocardial infarction or peripheral arterial dis-
ease without a history of stroke before random-
ization. In addition, an analysis of efficacy that was 
restricted to patients with the qualifying diagno-
sis of myocardial infarction alone was specified in 
the original analysis plan before the board’s rec-
ommendation.
The efficacy analyses were performed with the 
use of a Cox proportional-hazards model, with the 
study group and stratification factors at random-
ization as covariates. Cumulative event rates were 
calculated with the use of the Kaplan–Meier meth-
od at 3 years. Safety analyses were performed 
among patients who received one or more doses of 
a study drug and included events through 60 days 
after premature cessation of study therapy or 
30 days after a final visit at the conclusion of the 
trial. On the basis of one planned interim analysis 
of efficacy, a P value of less than 0.049 was con-
sidered to indicate statistical significance for the 
final analysis,8 and a P value of less than 0.05 was 
deemed to indicate a significant interaction. All 
reported P values are two-sided.
R esult s
Study Patients and Follow-up
From September 26, 2007, through November 13, 
2009, a total of 26,449 patients were enrolled in 
the trial. Of these, 13,225 were randomly assigned 
to receive vorapaxar, and 13,244 to receive placebo 
(Fig. S1 in the Supplementary Appendix).
Baseline characteristics of the patients are 
shown in Table 1. The qualifying diagnosis for 
enrollment was myocardial infarction in two thirds 
of the patients, stroke in 18%, and peripheral arte-
rial disease in 14%. A total of 94% of the patients 
were treated with aspirin. At baseline, a thieno-
pyridine was being administered in a majority of 
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patients with a qualifying diagnosis of myocardial 
infarction but in only a minority of patients with 
a qualifying diagnosis of stroke or peripheral ar-
terial disease. Only 177 patients (0.7%) received 
prasugrel during the study.
The longest duration of follow-up was 49 
months, with a median follow-up of 30 months 
(interquartile range, 24 to 36). Details of follow-
up and loss to follow-up are provided in the Sup-
plementary Appendix. The last date of patient 
Table 1. Baseline Characteristics of the Patients.*
Characteristic
Vorapaxar  
(N = 13,225)
Placebo 
(N = 13,224)
Demographic
Age
Median — yr 61 61
Interquartile range — yr 53–69 53–69
≥75 yr — no. (%) 1,514 (11.4) 1,506 (11.4)
Female sex — no. (%) 3,154 (23.8) 3,172 (24.0)
White race — no./total no. (%)† 11,562/13,218 (87.5) 11,524/13,219 (87.2)
Qualifying type of atherosclerosis — no. (%)
Myocardial infarction 8,898 (67.3) 8,881 (67.2)
Ischemic stroke 2,435 (18.4) 2,448 (18.5)
Peripheral arterial disease 1,892 (14.3) 1,895 (14.3)
Selected clinical characteristics — no./total no. (%)
Diabetes mellitus 3,368/13,224 (25.5) 3,356/13,220 (25.4)
Hypertension 9,047/13,225 (68.4) 9,127/13,219 (69.0)
Hyperlipidemia 10,983/13,224 (83.1) 11,011/13,220 (83.3)
Current smoker 2,748/13,225 (20.8) 2,750/13,220 (20.8)
Any coronary artery disease 10,329/13,223 (78.1) 10,362/13,215 (78.4)
Previous coronary revascularization 8,641/13,223 (65.3) 8,620/13,218 (65.2)
Any peripheral arterial disease 2,901/13,224 (21.9) 2,944/13,218 (22.3)
Previous cerebrovascular event 3,139/13,223 (23.7) 3,129/13,220 (23.7)
Estimated glomerular filtration rate <60 ml/min/1.73 m2‡§ 2,112/13,056 (16.2) 1,972/13,057 (15.1)
Use of antiplatelet agents — no./total no. (%)
Qualifying myocardial infarction
Aspirin 8,732/8,898 (98.1) 8,716/8,881 (98.1)
Thienopyridine 6,934/8,898 (77.9) 6,960/8,881 (78.4)
Qualifying peripheral arterial disease
Aspirin 1,661/1,892 (87.8) 1,671/1,895 (88.2)
Thienopyridine 696/1,892 (36.8) 698/1,895 (36.8)
Qualifying stroke
Aspirin 1,978/2,435 (81.2) 1,976/2,448 (80.7)
Thienopyridine 574/2,435 (23.6) 580/2,448 (23.7)
Dipyridamole 475/2,435 (19.5) 474/2,448 (19.4)
Use of other medications — no. (%)
Lipid-lowering agent§ 12,032 (91.0) 12,131 (91.7)
Angiotensin-converting–enzyme inhibitor or angiotensin- 
receptor blocker§
9,714 (73.5) 9,871 (74.6)
* There were no significant differences between the two study groups, except as indicated.
† Race was self-reported.
‡ The glomerular filtration rate was estimated with the use of the Modification of Diet in Renal Disease (MDRD) formula.
§ P<0.05.
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contact was December 23, 2011, and the trial data-
base was locked on January 9, 2012.
Efficacy End Points
At 3 years, the primary end point of cardiovascular 
death, myocardial infarction, or stroke had oc-
curred in 1028 patients (9.3%) in the vorapaxar 
group, as compared with 1176 patients (10.5%) in 
the placebo group (hazard ratio, 0.87; 95% confi-
dence interval [CI], 0.80 to 0.94; P<0.001) (Table 
2 and Fig. 1A). The major secondary end point of 
cardiovascular death, myocardial infarction, stroke, 
or urgent coronary revascularization occurred in 
1259 patients (11.2%) in the vorapaxar group, as 
compared with 1417 patients (12.4%) in the placebo 
group (hazard ratio, 0.88; 95% CI, 0.82 to 0.95; 
P = 0.001) (Table 2 and Fig. 1B). The rate of cardio-
vascular death or myocardial infarction was re-
duced from 8.2% among patients in the placebo 
group to 7.3% among patients in the vorapaxar 
group (P = 0.002) (Table 2, and Fig. S2 in the Sup-
plementary Appendix). Individual components of 
these composite end points are also shown in 
Table 2. The rate of death from any cause did not 
differ significantly between the vorapaxar group 
and the placebo group (5.0% and 5.3%, respec-
tively; hazard ratio, 0.95; 95% CI, 0.85 to 1.07; 
P = 0.41). (Additional prespecified efficacy end 
points are shown in Tables S1 and S2 in the Sup-
plementary Appendix.)
Among patients with no history of stroke, the 
primary end point occurred in 8.3% of patients in 
the vorapaxar group, as compared with 9.6% of 
those in the placebo group (hazard ratio, 0.84; 
95% CI, 0.76 to 0.93; P<0.001) (Table S3 in the 
Supplementary Appendix). There was no signifi-
cant heterogeneity for the benefit of vorapaxar on 
the rate of cardiovascular death, myocardial infarc-
tion, or stroke across most of the major subgroups 
examined, including those defined according to 
the use or nonuse of a thienopyridine (Fig. S3 in 
the Supplementary Appendix). However, among 
patients who weighed less than 60 kg, the use of 
vorapaxar did not have a favorable influence on 
this outcome (P = 0.03 for interaction). Additional 
analyses of efficacy in subgroups that were de-
fined according to the qualifying diagnosis of 
atherosclerosis (myocardial infarction, stroke, or 
peripheral arterial disease) and the presence or 
absence of a history of stroke are provided in Ta-
ble S3 and Figure S3 in the Supplementary Ap-
pendix.
Safety End Points
The major safety end point of moderate or severe 
bleeding (according to GUSTO criteria) occurred 
in 438 patients (4.2%) in the vorapaxar group, as 
compared with 267 patients (2.5%) in the place-
bo group (hazard ratio, 1.66; 95% CI, 1.43 to 
1.93; P<0.001) (Table 2 and Fig. 2A). There was 
no evidence of heterogeneity in the effect of vora-
paxar on moderate or severe bleeding in major 
subgroups (Fig. S4 in the Supplementary Appen-
dix). Rates of TIMI clinically significant bleeding 
(Fig. 2B) and rates of TIMI major bleeding not re-
lated to coronary-artery bypass grafting were also 
both significantly increased in the vorapaxar group 
as compared with the placebo group (P<0.001) 
(Table 2).
Overall, intracranial hemorrhage occurred in 
102 patients (1.0%) in the vorapaxar group, as 
compared with 53 patients (0.5%) in the placebo 
group (hazard ratio, 1.94; 95% CI, 1.39 to 2.70; 
P<0.001) (Table 2, and Fig. S5 in the Supplementary 
Appendix). Fatal bleeding occurred in 29 patients 
(0.3%) in the vorapaxar group, as compared with 
20 patients (0.2%) in the placebo group (hazard 
ratio, 1.46; 95% CI, 0.82 to 2.58; P = 0.19). Among 
patients with a history of stroke, the rate of intra-
cranial hemorrhage in the vorapaxar group was 
2.4%, as compared with 0.9% in the placebo group 
(P<0.001), with corresponding rates of fatal bleed-
ing of 0.5% and 0.3% (P = 0.46) (Table S3 in the 
Supplementary Appendix). Among patients with-
out a history of stroke, the rates of intracranial 
hemorrhage were lower in the two study groups 
(0.6% in the vorapaxar group and 0.4% in the pla-
cebo group, P = 0.049), as were the rates of fatal 
bleeding (0.3% and 0.2%, respectively; P = 0.30). 
Additional safety analyses are shown in Tables S3 
and S4 in the Supplementary Appendix.
Net Clinical Outcome
A composite end point termed net clinical outcome, 
comprising the primary efficacy and safety end 
points, was prespecified (Table 2). The composite 
of cardiovascular death, myocardial infarction, 
stroke, or GUSTO moderate or severe bleeding 
occurred in 1315 patients (11.7%) in the vora-
paxar group and in 1358 patients (12.1%) in the 
placebo group (hazard ratio, 0.97; 95% CI, 0.90 to 
1.04; P = 0.40). Other net clinical outcomes in all 
patients and in patients without stroke are re-
ported in Table 2, and Table S4 in the Supple-
mentary Appendix.
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Discussion
In previous studies, it has not been established 
whether the addition of another antiplatelet agent 
to aspirin therapy would reduce the rate of throm-
botic events in patients with stable atherosclerotic 
disease.4 In our large randomized trial, the PAR-1 
antagonist vorapaxar significantly reduced the 
rate of cardiovascular death, myocardial infarction, 
or stroke in patients with a history of athero-
thrombosis who were receiving standard therapy. 
However, the reduction in cardiovascular events 
came at the cost of increased bleeding. This ben-
efit and risk emerged early and continued to accrue 
throughout follow-up. Our findings show that in-
hibition of another platelet pathway in addition to 
Table 2. Efficacy and Bleeding End Points at 3 Years.*
End Point Vorapaxar Placebo
Hazard Ratio
(95% CI) P Value
number (percent)
Efficacy 13,225 13,224
Cardiovascular death, myocardial infarction,  
or stroke
1028 (9.3) 1176 (10.5) 0.87 (0.80–0.94) <0.001
Cardiovascular death, myocardial infarction, stroke, 
or urgent coronary revascularization
1259 (11.2) 1417 (12.4) 0.88 (0.82–0.95) 0.001
Cardiovascular death or myocardial infarction 789 (7.3) 913 (8.2) 0.86 (0.78–0.94) 0.002
Cardiovascular death 285 (2.7) 319 (3.0) 0.89 (0.76–1.04) 0.15
Myocardial infarction 564 (5.2) 673 (6.1) 0.83 (0.74–0.93) 0.001
Stroke
Any stroke 315 (2.8) 324 (2.8) 0.97 (0.83–1.14) 0.73
Ischemic stroke 250 (2.2) 294 (2.6) 0.85 (0.72–1.01) 0.06
Urgent coronary revascularization 279 (2.5) 316 (2.6) 0.88 (0.75–1.03) 0.11
Death from any cause 540 (5.0) 565 (5.3) 0.95 (0.85–1.07) 0.41
Bleeding 13,186 13,166
GUSTO moderate or severe 438 (4.2) 267 (2.5) 1.66 (1.43–1.93) <0.001
TIMI
Clinically significant 1759 (15.8) 1241 (11.1) 1.46 (1.36–1.57) <0.001
Non–CABG-related major 287 (2.8) 198 (1.8) 1.46 (1.22–1.75) <0.001
CABG-related major† 11 (7.6) 10 (6.1) 1.13 (0.48–2.66) 0.79
Fatal 29 (0.3) 20 (0.2) 1.46 (0.82–2.58) 0.19
Intracranial 102 (1.0) 53 (0.5) 1.94 (1.39–2.70) <0.001
Intracerebral 89 (0.8) 41 (0.4) 2.19 (1.51–3.17) <0.001
Subdural or epidural 12 (0.1) 10 (0.1) 1.20 (0.52–2.79) 0.67
Unknown 1 (<0.1) 2 (<0.1)
Net clinical outcome 13,186 13,166
Cardiovascular death, myocardial infarction, stroke, 
or GUSTO moderate or severe bleeding
1315 (11.7) 1358 (12.1) 0.97 (0.90–1.04) 0.40
Cardiovascular death, myocardial infarction, stroke, 
urgent coronary revascularization, or 
GUSTO moderate or severe bleeding
1526 (13.4) 1593 (14.0) 0.96 (0.89–1.02) 0.20
Death from any cause, myocardial infarction, stroke, 
or GUSTO severe bleeding
1322 (11.9) 1436 (12.8) 0.92 (0.85–0.99) 0.02
* Percentages are cumulative Kaplan–Meier event rates at 3 years. The stroke component in all efficacy end points in-
cluded all ischemic and hemorrhagic strokes, unless otherwise specified. Urgent coronary revascularization was defined 
by recurrent ischemia leading to urgent coronary revascularization. CABG denotes coronary-artery bypass grafting, 
GUSTO Global Use of Strategies to Open Occluded Coronary Arteries, and TIMI Thrombolysis in Myocardial Infarction.
† CABG-related major bleeding was assessed in 175 patients in the vorapaxar group and 201 patients in the placebo group.
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that targeted by standard antiplatelet therapy for 
secondary prevention reduces the risk of recurrent 
thrombotic events in patients with previous athero-
thrombosis. This benefit was evident particularly in 
those whose qualifying diagnosis for participation 
in the trial was myocardial infarction.
The results of our study establish that interrup-
tion of the platelet-directed cellular actions of 
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Figure 1. Kaplan–Meier Rates of Cardiovascular Events.
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Figure 2. Kaplan–Meier Rates of Bleeding.
Panel A shows the estimated rates of moderate or severe bleeding, according to Global Use of Strategies to Open 
Occluded Coronary Arteries (GUSTO) criteria. Panel B shows the rates of clinically significant bleeding, according to 
Thrombolysis in Myocardial Infarction (TIMI) criteria, defined as any clinically overt bleeding that requires unplanned 
treatment or laboratory evaluation or that meets the criteria for TIMI minor or major bleeding.
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thrombin, suggested in preclinical studies to be 
pivotal to thrombosis,10 translates into a clinical 
effect on major thrombotic events. In our study, 
antagonism of PAR-1 was complementary to inhi-
bition of the thromboxane A2 and P2Y12-receptor 
pathways with aspirin and thienopyridines, with 
respect to the protective effect against recurrent 
thrombosis. We did not find evidence of signifi-
cant heterogeneity of the effect of vorapaxar on 
the basis of treatment with clopidogrel. When 
vorapaxar was studied in the TRACER trial for the 
management of acute coronary syndromes, there 
was a nonsignificant trend toward a reduction in 
the rate of cardiovascular death, myocardial infarc-
tion, stroke, recurrent ischemia with hospitaliza-
tion, or urgent coronary revascularization and an 
exploratory finding of a reduction in the rate of 
cardiovascular death, myocardial infarction, or 
stroke, along with a significant increase in the 
risk of intracranial hemorrhage.9 Previous small-
er phase 2 trials of vorapaxar11,12 and of atopax-
ar,13,14 another PAR-1 antagonist, have also re-
vealed trends toward reductions in recurrent 
thrombotic events but without evidence of an in-
creased risk of intracranial hemorrhage.
During the trial, the data and safety monitor-
ing board recommended the discontinuation of 
vorapaxar in patients with a history of stroke on 
the basis of an excess of intracranial hemorrhage 
in such patients. We therefore carried out a sepa-
rate analysis that was confined to patients without 
a history of stroke and found a significant benefit 
in this subgroup. In addition, in a prespecified 
analysis involving patients with a qualifying diag-
nosis of myocardial infarction, vorapaxar reduced 
the relative risk of the primary end point by 20%. 
In the largest previous placebo-controlled trial of 
antiplatelet therapy for secondary prevention in 
patients with stable atherothrombosis or at high 
risk for vascular disease, clopidogrel plus aspirin 
was no better than aspirin alone in the overall 
cohort.4 Nevertheless, in an exploratory analysis 
involving 3846 patients with previous myocardial 
infarction in that trial, the addition of clopidogrel 
reduced the risk of cardiovascular death, myocar-
dial infarction, or stroke by 23%.15 Our trial in-
volving a substantially larger number of patients 
with a history of myocardial infarction shows that 
the addition of another antiplatelet agent to aspirin 
therapy over the long term can achieve further 
reductions in recurrent atherothrombotic events in 
this population.
The reduction in thrombotic events with vora-
paxar came with significant increases in bleeding. 
Although our findings show that additional reduc-
tions in atherothrombosis can be achieved, this 
benefit must be weighed against the increase in 
bleeding risk. In the overall trial cohort, there was 
no significant between-group difference in the 
prespecified net clinical outcome (including both 
thrombotic end points and moderate or severe 
bleeding). However, weighed against the risk of 
severe bleeding, particularly in patients without 
a history of stroke, the net clinical outcome was 
improved in patients receiving vorapaxar.
The results of our study also add to the accu-
mulating evidence of a heightened risk of intra-
cranial hemorrhage among patients with a history 
of stroke who are treated with potent antiplatelet 
therapy.2,16,17 As with the use of third-generation 
P2Y12 inhibitors, such as prasugrel, any clinical 
use of vorapaxar would have to be based on an 
appropriate selection of patients, with the risk of 
bleeding balanced against that of recurrent throm-
botic events. We have previously identified crite-
ria for selecting patients who are more likely to 
have improved net clinical outcomes with potent 
antiplatelet therapy.2,18 In our study, the relative 
risk of bleeding, including intracranial hemor-
rhage, showed a similar significant increase in the 
vorapaxar group among patients with and those 
without a history of stroke. However, the absolute 
rate of intracranial hemorrhage (0.2% per year) 
among patients without a history of stroke was 
substantially lower than that among patients with 
such a history (0.8% per year). The rate of fatal 
bleeding was not significantly increased in the 
vorapaxar group.
In conclusion, the addition of vorapaxar to stan-
dard therapy reduced the risk of cardiovascular 
death, myocardial infarction, or stroke among pa-
tients with stable atherosclerosis, a benefit that 
was most apparent in patients with a history of 
myocardial infarction. Vorapaxar also increased 
the risk of moderate or severe bleeding, including 
intracranial hemorrhage, with the latter occurring 
most frequently in patients with a history of stroke.
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